Marcel Kemper
Overview
Explore the profile of Marcel Kemper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kemper M, Elges S, Kies P, Wiebe K, Lenz G, Bleckmann A, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2813-2827.
PMID: 39507015
Background And Objective: The standard first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor () mutations or anaplastic lymphoma kinase () fusions is...
2.
Wustmann N, Humberg V, Vieler J, Seitzer K, von Ruden S, Juratli M, et al.
Lab Invest
. 2024 Sep;
104(10):102142.
PMID: 39307310
Circulating tumor cells and liquid biopsy-based biomarkers might one day play a crucial role in the treatment decision process for patients of several cancer entities. However, clinical studies on liquid...
3.
Fabritz L, Fortmueller L, Gehmlich K, Kant S, Kemper M, Kucerova D, et al.
Biomedicines
. 2024 May;
12(5).
PMID: 38790949
Desmoglein-2 mutations are detected in 5-10% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Endurance training accelerates the development of the ARVC phenotype, leading to earlier arrhythmic events. Homozygous mutant...
4.
Kemper M, Soltani Germy P, Acker F, Luan J, Griesinger F, Tufman A, et al.
Oncol Res Treat
. 2024 Apr;
47(6):312-315.
PMID: 38574467
No abstract available.
5.
Acker F, Luan J, Soltani Germy P, Kemper M, Blasi M, Griesinger F, et al.
Oncol Res Treat
. 2024 Mar;
47(6):306-311.
PMID: 38527447
No abstract available.
6.
Schone N, Kemper M, Menck K, Evers G, Krekeler C, Schulze A, et al.
J Extracell Vesicles
. 2024 Mar;
13(3):e12418.
PMID: 38453684
Immunotherapy has revolutionized the treatment of patients with non-small cell lung cancer (NSCLC). High expression of tissue PD-L1 (tPD-L1) is currently the only approved biomarker for predicting treatment response. However,...
7.
Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Luders H, et al.
J Thorac Oncol
. 2023 Dec;
19(5):803-817.
PMID: 38096950
Introduction: Programmed death-ligand 1 expression currently represents the only validated predictive biomarker for immune checkpoint inhibition in metastatic NSCLC in the clinical routine, but it has limited value in distinguishing...
8.
Kemper M, Krekeler C, Menck K, Lenz G, Evers G, Schulze A, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900221
As lung cancer has the highest cancer-specific mortality rates worldwide, there is an urgent need for new therapeutic and diagnostic approaches to detect early-stage tumors and to monitor their response...
9.
Krekeler C, Reitnauer L, Bacher U, Khandanpour C, Steger L, Boeckel G, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428605
Background: Two-dose COVID-19 vaccination often results in poor humoral response rates in patients with hematologic malignancies (HMs); yet responses to COVID-19 booster vaccines and the risk of COVID-19 infection post-booster...
10.
Kemper M, Evers G, Schulze A, Sperveslage J, Schulke C, Lenz G, et al.
Oncotarget
. 2022 Nov;
13:1216.
PMID: 36342457
No abstract available.